Add-on Acquisition • Life Science

Alfasigma Acquires Intercept

On September 26, 2023, Alfasigma acquired life science company Intercept

Acquisition Context

This is Alfasigma’s 2nd transaction in the Life Science sector.
This is Alfasigma’s 1st transaction in the United States.
This is Alfasigma’s 1st transaction in New Jersey.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	September 26, 2023
Target	Intercept
Sector	Life Science
Buyer(s)	Alfasigma
Deal Type	Add-on Acquisition
Advisor(s)	Barclays Investment Bank Centerview Partners (Financial) Skadden, Arps, Slate, Meagher & Flom (Legal)

Target Company

Intercept

Morristown, New Jersey, United States

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). Intercept is based in Morristown, New Jersey

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Alfasigma

Bologna, Italy

Category	Company
Sector	Life Science
Revenue	1.0B EUR (2021)

DESCRIPTION

Alfasigma is a multinational pharmaceutical company with 3 production plants in Italy and 2 abroad, and on-site presence in 17 markets plus an indirect presence in about 70 countries. Alfasigma is based in Bologna, Italy.

Deal Context for Buyer	#
Overall	2 of 2
Sector: Life Science	2 of 2
Type: Add-on Acquisition	2 of 2
State: New Jersey	1 of 1
Country: United States	1 of 1
Year: 2023	1 of 1

PREVIOUS DEAL

DATE	TARGET	DEAL TYPE	VALUE
2022-08-02	Sofar Trezzano Rosa, Italy Sofar is an Italian pharmaceutical company active in the research, production, and marketing of drugs, medical devices, and dietary supplements -with a long-standing tradition and well-known to professionals and patients. Sofar was formed in 1968 and is based in Trezzano Rosa, Italy.	Buy	-

DATE

TARGET

DEAL TYPE

VALUE

2022-08-02

Sofar

Trezzano Rosa, Italy

Sofar is an Italian pharmaceutical company active in the research, production, and marketing of drugs, medical devices, and dietary supplements -with a long-standing tradition and well-known to professionals and patients. Sofar was formed in 1968 and is based in Trezzano Rosa, Italy.

Buy

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - New Jersey M&A - United States M&A - 2023 M&A